The purpose of this study was to analyze the efficacy of neoadjuvant fluorouracil-cisplatin chemotherapy combined with radiotherapy for anal cancer.
Methods
Fourteen patients with epidermoid carcinoma of the anal canal were analyzed. Treatment consisted of three cycles of 5-fluorouracil (1000 mg/m2 bolus on days 1-5) and cisplatin (60 mg/m2 bolus on day 1) followed by 50.4 Gy to the pelvis and perineum over 5.5 weeks. Both inguinal lymphatics were irradiated with an identical dose schedule. The median follow-up was 78 months.
Results
Five-year overall survival rate and sphincter preservation rate was 85.1% and 85.7%, respectively. Response to chemoradiotherapy was the only significant factor with univariate analysis (P = 0.031). There were no complications of RTOG grade 3 or higher.
Conclusions
Neoadjuvant chemotherapy with a cisplatin-based regimen rather than concurrent regimen plus radiotherapy may decrease complications without compromising survival or sphincter preservation.
TouboulE., SchliengerM., BuffatL., OzsahinM., BelkacemiY., PeneF., BalossoJ., LefkopoulosD., ParcR., TiretE., GallotD., MalafosseM., LaugierA.: Conservative versus nonconservative treatment of epidermoid carcinoma of anal canal for tumors longer or equal to 5 centimeters: a retrospective comparison. Cancer, 75: 786–793, 1995.
6.
NigroN., VaitkeviciusV., ConsidineB.: Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 15: 354–356, 1974.
7.
BartelinkH., RoelofsenF., EschwegeF., RougierP., BossetJ.F., GonzalezD.G., PeiffertD., van GlabbekeM., PierartM.: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol, 15: 2040–2049, 1997.
8.
UKCCCR Anal Cancer Trial Working Party:Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet, 348: 1049–1054, 1996.
9.
American Joint Committee on Cancer:AJCC Cancer Staging Manual, 5th edn, Lippincott-Raven, Philadelphia, 1997.
10.
SvenssonC., GoldmanS., FribergB., GlimeliusB.: Induction chemotherapy and radiotherapy in loco-regionally advanced epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys, 41: 863–867, 1998.
11.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457–481, 1958.
12.
CoxD.R.: Regression models and life tables. J R Stat Soc, 34: 187–202, 1972
13.
FlamM., JohnM., PajakT.F., PetrelliN., MyersonR., DoggettS., QuiveyJ., RotmanM., KermanH., CoiaL., MurrayK.: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol, 14: 2527–2539, 1996.
14.
DociR., ZucaliR., La MonicaG., MeroniE., KendaR., EboliM., LozzaL.: Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol, 14: 3121–3125, 1996.
15.
GerardJ.P., AyzacL., HunD., RomestaingP., CoquardR., ArdietJ.M., MornexF.: Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol, 46: 249–256, 1998.
16.
MartensonJ.A., LipsitzS.R., WagnerH.Jr., KaplanE.H., OttemanL.A., SchuchterL.M., MansourE.G., TalamontiM.S., BensonAB3rd: Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys, 35: 745–749, 1996.
17.
MeropolN.J., NiedzwieckiD., ShankB., ColacchioT., EllertonJ., ValoneF., HollisD., BudingerS., MayerR.J.: Combined-modality therapy for poor risk anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB) (Abstr). Proc ASCO, 18: 245, 1999.
18.
PeiffertD., SeitzJ.F., RougierP., FrancoisE., CvitkovicF., MirabelX., NascaS., DucreuxM., Hannoun-LeviJ.M., LusinchiA., DebrigodeE., ConroyT., PignonJ.P., GerardJ.P.: Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol, 8: 575–581, 1997.
19.
HughesL.L., RichT.A., DelclosS.L., AjaniJ.A., MartinR.G.: Radiotherapy for anal cancer: experience from 1979 to 1987. Int J Radiat Oncol Biol Phys, 17: 1153–1160, 1989.
